Renal & Urology News1d
Local Radiation Therapy for mHSPC Lowers Risk for Prostate Cancer-Related Events
Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).
Pharmabiz3d
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Medpage Today on MSN3d
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...
Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight
DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...
Renal & Urology News4d
Prostate Cancer Triplet Therapy Including Darolutamide May Be Less Cardiotoxic
A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
Orion Oyj: Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU
ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion's collaboration ...